Trk receptor modulator

ACD856 is an experimental oral drug from the Swedish company AlzeCure Pharma. It is a positive allosteric modulator of the Trk receptors: it does not replace BDNF or NGF but makes TrkA, TrkB and TrkC respond more strongly to them. In mice and rats it reversed drug-induced and age-related memory deficits and shortened immobility in the forced swim test. In people it has only been through phase 1: single doses up to 150 mg and seven days at up to 90 mg a day were well tolerated in healthy volunteers, it reached the cerebrospinal fluid, and it shifted the resting EEG, but no published trial has tested whether it improves memory or mood. Every published study comes from the developer.